全文获取类型
收费全文 | 8164篇 |
免费 | 768篇 |
国内免费 | 515篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 107篇 |
妇产科学 | 135篇 |
基础医学 | 888篇 |
口腔科学 | 109篇 |
临床医学 | 1053篇 |
内科学 | 1104篇 |
皮肤病学 | 49篇 |
神经病学 | 386篇 |
特种医学 | 495篇 |
外国民族医学 | 5篇 |
外科学 | 826篇 |
综合类 | 1514篇 |
现状与发展 | 4篇 |
一般理论 | 3篇 |
预防医学 | 619篇 |
眼科学 | 164篇 |
药学 | 791篇 |
14篇 | |
中国医学 | 511篇 |
肿瘤学 | 614篇 |
出版年
2024年 | 12篇 |
2023年 | 116篇 |
2022年 | 208篇 |
2021年 | 375篇 |
2020年 | 330篇 |
2019年 | 254篇 |
2018年 | 244篇 |
2017年 | 226篇 |
2016年 | 236篇 |
2015年 | 356篇 |
2014年 | 473篇 |
2013年 | 370篇 |
2012年 | 573篇 |
2011年 | 662篇 |
2010年 | 421篇 |
2009年 | 322篇 |
2008年 | 403篇 |
2007年 | 413篇 |
2006年 | 417篇 |
2005年 | 439篇 |
2004年 | 343篇 |
2003年 | 304篇 |
2002年 | 303篇 |
2001年 | 240篇 |
2000年 | 267篇 |
1999年 | 223篇 |
1998年 | 134篇 |
1997年 | 145篇 |
1996年 | 111篇 |
1995年 | 94篇 |
1994年 | 93篇 |
1993年 | 53篇 |
1992年 | 57篇 |
1991年 | 44篇 |
1990年 | 44篇 |
1989年 | 32篇 |
1988年 | 24篇 |
1987年 | 17篇 |
1986年 | 22篇 |
1985年 | 11篇 |
1984年 | 9篇 |
1983年 | 14篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 5篇 |
排序方式: 共有9447条查询结果,搜索用时 234 毫秒
1.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
2.
舌癌患者手术及放化疗后会出现构音障碍、吞咽困难、口腔黏膜炎、口干、营养不良等并发症,使患者生存质量下降,甚至导致肿瘤的复发转移,影响生存期,单一方法往往顾此失彼。依托于中国中医科学院西苑医院肿瘤康复基地,杨宇飞教授在国内外调研考察基础上,结合中国国情,构建了一种“门诊多学科肿瘤康复模式”,在舌癌康复方面,以患者为中心,以中医肿瘤内科为主导,多学科共同参与,结合康复科、口腔科、营养科、药剂科等各科优势,形成全程个体化规范序贯康复方案,对患者及早进行康复,在放疗前进行预防性干预尤其重要,使患者能够快速缓解手术和放疗的不良反应,患者获益明显。现取两个典型案例总结其舌癌多学科康复的经验,以期为舌癌的康复提供借鉴。 相似文献
3.
4.
5.
miR-30c has been acknowledged as a tumor suppressor in various human cancers, such as ovarian cancer, gastric cancer, and prostate cancer. However, the role of miR-30c in glioblastoma (GBM) needs to be investigated.
In our study, we found that the expression of miR-30c was significantly downregulated in GBM tissues and
cell lines. We found that overexpression of miR-30c inhibited cellular proliferation of GBM cells in vitro and
in vivo. More GBM cells were arrested in the G0 phase after miR-30c overexpression. Moreover, we showed
that miR-30c overexpression suppressed the migration and invasion of GBM cells. Mechanistically, we found
that SOX9 was a direct target of miR-30c in GBM cells. Overexpression of miR-30c inhibited the mRNA
and protein levels of SOX9 in GBM cells. Moreover, there was a negative correlation between the expression
of miR-30c and SOX9 in GBM tissues. Finally, we showed that restoration of SOX9 in GBM cells reversed
the proliferation, migration, and invasion of GBM cells transfected with miR-30c mimic. Collectively, our
results demonstrated that miR-30c suppressed the proliferation, migration, and invasion of GBM cells via
targeting SOX9. 相似文献
6.
目的 解析真实世界中乳腺恶性肿瘤患者的人群特征、诊断特征、中西医用药特征,为乳腺癌的临床防治提供参考。方法 采集2002年2月至2015年5月全国60家三级甲等医 院信息系统(Hospital Information System,HIS)中,出院诊断为“乳腺癌”的患者用药信息,采用SAS9.3统计软件,对人口学信息、诊断信息、医嘱用药信息等进行描述性分析。结果 39798例乳腺癌患者,平均年龄(50.93者,平均年龄)岁;多以门诊入院,入院病情以“一般”为主;合并疾病主要为高血压,骨肿瘤,联用西药以抑制肿瘤细胞增殖、治疗并发症、缓解放化疗不良反应为主;中医辨证以痰瘀互结证,气阴两虚证,肝气淤滞证,脾气亏虚证型最为常见,临床清热解毒剂、益气扶正剂,活血化瘀剂应用较多。结论 乳腺癌中西医结合治疗,联用药物广泛,临床治疗基本符合临床指南。 相似文献
7.
8.
本文报告1例围产期新型冠状病毒感染患者的诊治经过及围产结局。孕妇孕37周+2因"严重肝功能异常"行急诊剖宫产娩出一活男婴。术后第2天产妇出现发热,经咽拭子核酸检测确诊新型冠状病毒感染。经隔离及对症支持治疗12 d,连续2次核酸检测阴性痊愈出院。患者血、尿、乳汁及新生儿咽拭子均未检测到新型冠状病毒核酸。新生儿心肌酶升高,隔离14 d后痊愈出院。 相似文献
9.
10.
Huimin Bai Guihua Sha Dongyan Cao Jiaxin Yang Jie Chen Yue Wang Jinghe Lang Keng Shen Zhenyu Zhang 《Medicine》2015,94(27)
The purpose of this study was to evaluate the effects of salvage chemotherapy on recurrent or persistent ovarian clear cell carcinoma (CCC) with the goal of identifying a more rational treatment regimen for this lethal disease.The medical records of patients with CCC were retrospectively reviewed to select patients that were subsequently treated for recurrent or persistent disease.Of the 164 women with recurrent or persistent CCC, 485 chemotherapy courses with 1766 cycles were administered. Overall, the clinical benefit rate (CBR) was 39.4%, and the mean progression-free survival (PFS) was 4.5 months. Grade 3/4 toxicities occurred in 94 courses (19.4%). The CBR for TC was 45.1%, with a PFS of 3.7 months. Compared to that of TC, the CBRs for PC and CC were significantly lower (P = 0.020 and 0.021, respectively). The CBRs and PFS for PAF-C were slightly higher (P = 0.518 and 0.077, respectively), but showed a significantly higher adverse event rate (AER, P = 0.039). The CBR for bevacizumab was 50% with an extraordinarily long PFS (49.8 months). Gemcitabine and oxaliplatin had similar values for CBRs (44.4% and 44.1%) and PFS (2.5 and 3.4 months), respectively. Docetaxel (weekly) exhibited a notably low AER of 2.7%, and topotecan was associated with a relatively long PFS (7.7 months).For cis/carboplatin-pretreated patients, the existing active agents, such as oxaliplatin, gemcitabine, topotecan, and especially bevacizumab, are promising. Docetaxel (weekly) is well tolerated and might offer a particularly viable option for heavily pretreated patients. However, additional research to identify for a continued search for the optimal combination of chemotherapeutics or novel agents is still warranted. 相似文献